



For Immediate Release

January 12, 2022

Acuitas Therapeutics Names Miranda Lam as Chief Legal Officer & Sr. Director, Business Development

Vancouver, B.C. – Miranda Lam has joined Acuitas Therapeutics as Chief Legal Officer & Sr. Director, Business Development, Acuitas President and CEO, Dr. Thomas Madden, announced recently. Ms. Lam comes to the newly created position on the Acuitas executive team from the Canadian national law firm McCarthy Tétrault LLP, where she was an equity partner.

Ms. Lam received her Bachelor of Laws from the University of British Columbia. She has been recognized as a leading lawyer in a range of respected independent publications such as *Chambers Canada*, *Best Lawyers in Canada* and *Benchmark Canada: The Definitive Guide to Canada's Leading Litigation Firms and Attorneys*. She was named in *Vancouver Magazine's* Power 50 List of the City's Most Influential People (2018) and was identified as a Leading Lawyer Under 40 by *Lexpert* (2017), "Best 40 Under 40" Lawyer by the National Asian Pacific American Bar Association (2015), and was the recipient of the Association of Women in Finance's PEAK Women in Finance "Rising Star" Award (2014). She was also named as one of *Business in Vancouver's* "Forty Under 40" (2013). Ms. Lam is a recognized speaker and advocate for diversity and inclusion and sits on the board of directors of the BC Cancer Foundation.

"Acuitas has increased its global profile over the past two years as our lipid nanoparticle delivery system plays a key role in mRNA vaccines, including the BioNTech/Pfizer COVID-19 vaccine COMIRNATY®. Miranda's extensive legal and business experience, exceptional relationship-building skills, and her collaborative, team-focused approach will be invaluable to our organization," said Dr Madden. He added, "Everyone on the team is looking forward to working with Miranda as we continue to support our partners to bring new therapeutics to patients."

About Acuitas Therapeutics

Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and biotechnology companies and academic institutes to advance nucleic acid therapeutics into clinical trials and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized capabilities in delivery technology. Acuitas Therapeutics has agreements in place with several partners to use its



proprietary lipid nanotechnology in the development of COVID-19 vaccines. These include Pfizer/BioNTech for COMIRNATY[®], which has received full approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other countries.

-END-